Protagenic Therapeutics, Inc. (PTIX)


-0.04 (-1.92%)

Dr. Garo H. Armen Ph.D.
NASDAQ Capital Market

Protagenic Therapeutics, Inc., a biopharmaceutical company, engages in the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. Its lead compound is PT00114, a synthetic form of teneurin carboxy-terminal associated peptide, an endogenous brain signaling peptide that can dampen overactive stress responses. The company is based in New York, New York.